Fourth Quarter & Full Year 2022 Financial & Business Update

Multi-Product Commercial Portfolio, Label Expansions and Differentiated Pipeline Drive Strong Future Growth Seagen Multi-Product Company Focused on Oncology 4 Approved targeted oncology products with multiple label expansion opportunities ADC Expertise World-leading expertise in validated vedotin platform, exploring new payloads and linkers 18 Clinical programs in progress by YE23 to address areas of high unmet medical need 17 Countries Robust commercialization footprint that can be leveraged and expanded with fully owned novel assets Seagen 7

View entire presentation